Sorin gets Committee for Proprietary Medicinal Products (CPMP) approval for TecneMAB:
This article was originally published in Clinica
Sorin Biomedica's malignant melanoma imaging agent TecneMAB has been approved by the European Committee for Proprietary Medicinal Products. Although the decision was made on May 23rd it normally takes about two months for companies to receive written permission to begin marketing controlled products. Sorin, which is based in Saluggia, Italy, developed the technetium-99-labelled antibody in the mid-1980s.
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”